Pfizer (NYSE:PFE) Updates FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.800-3.000 for the period, compared to the consensus earnings per share estimate of 3.090. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.9 billion.

Pfizer Stock Down 3.3%

Shares of Pfizer stock opened at $25.56 on Wednesday. The business has a fifty day simple moving average of $25.11 and a 200 day simple moving average of $24.81. The stock has a market cap of $145.34 billion, a PE ratio of 14.86 and a beta of 0.46. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer has a 12 month low of $20.92 and a 12 month high of $27.69.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts predict that Pfizer will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFE shares. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Bank of America cut their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Guggenheim lifted their price target on shares of Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, November 24th. Finally, Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.28.

Hedge Funds Weigh In On Pfizer

Several hedge funds have recently modified their holdings of PFE. State Street Corp raised its holdings in Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after acquiring an additional 2,786,098 shares in the last quarter. Northern Trust Corp raised its stake in shares of Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares in the last quarter. Amundi boosted its holdings in shares of Pfizer by 10.8% in the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock valued at $1,096,380,000 after buying an additional 4,043,413 shares during the last quarter. Invesco Ltd. grew its stake in shares of Pfizer by 3.7% in the third quarter. Invesco Ltd. now owns 30,335,842 shares of the biopharmaceutical company’s stock valued at $772,957,000 after buying an additional 1,085,701 shares in the last quarter. Finally, Unisphere Establishment increased its holdings in Pfizer by 13.8% during the third quarter. Unisphere Establishment now owns 14,400,000 shares of the biopharmaceutical company’s stock worth $366,912,000 after buying an additional 1,750,000 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.